[PD-L1 expression in squamous cell carcinomas of the upper aerodigestive tract: Pathological challenges and therapeutic implications].
1/5 보강
PD-L1 immunohistochemical assessment has become an essential biomarker in the management of squamous cell carcinomas of the upper aerodigestive tract (UADT).
APA
Ménager J, Fabre C, et al. (2026). [PD-L1 expression in squamous cell carcinomas of the upper aerodigestive tract: Pathological challenges and therapeutic implications].. Bulletin du cancer. https://doi.org/10.1016/j.bulcan.2026.02.004
MLA
Ménager J, et al.. "[PD-L1 expression in squamous cell carcinomas of the upper aerodigestive tract: Pathological challenges and therapeutic implications].." Bulletin du cancer, 2026.
PMID
41862327 ↗
Abstract 한글 요약
PD-L1 immunohistochemical assessment has become an essential biomarker in the management of squamous cell carcinomas of the upper aerodigestive tract (UADT). The Combined Positive Score (CPS) is currently the gold standard method for quantifying PD-L1 expression. This article provides an update on the technical and interpretative aspects of the CPS, practical recommendations for pathologists, and associated therapeutic implications. Particular attention is paid to challenges such as reproducibility of scoring, antibody selection, and the integration of PD-L1 expression data in therapeutic decisions, especially in the context of immunotherapy. The objective is to provide pathologists with an up-to-date synthesis of best practices and to give clinicians a better understanding of the role of PD-L1 in the personalized management strategy for patients with UADT squamous cell carcinoma.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Targeting CPS1 attenuates lung cancer metastasis by regulating EMT through an epigenetic mechanism.
- Cadonilimab plus chemotherapy . PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study.
- Comparative outcomes with low-dose and standard-dose immune checkpoint inhibitors in microsatellite stable advanced gastric/gastroesophageal adenocarcinoma.
- Differentiation grade and combined positive score correlation in head and neck squamous cell carcinoma.
- Less pain, faster recovery: evaluating 8Fr vs. 22Fr chest tubes in thoracoscopic lung cancer resection.
- Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options.